Therefore, strategies targeting SLC5A3 can be used as novel therapeutic approaches for gemcitabine-resistant pancreatic cancer by enhancing tumor suppression and alleviating mitochondrial dysfunction. Here, SLC5A3 is linked to neoplasm.